TrialPath
← Back to searchRecruiting

Ruijin Neurobank of Alzheimer's Disease and Dementia

NCT05623124 · Ruijin Hospital
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
Neurovascular Coupling and Digital Biomarkers in Alzheimer's Disease
About this study
The observational study recruits participants from clinics and communities with cognitive impairment. Healthy volunteers will also be recruited as controls. Longitudinal observation of these participants will help demonstrate AD biomarkers' significance during AD pathogenesis. The investigators aim to build an aging population cohort covering the AD continuum and explore key biomarkers for AD. All participants will have multi-modal MRI scanning, PET scanning with different tracers, and blood test. With MRI scanning, the investigators are exploring the effect of neurovascular coupling in AD pathogenesis. In addition, the investigators are trying to find patterns/mapping of AD biomarkers with PET and blood tests. Beyond this, more neuroimage markers and digital biomarkers will be tested in the cohort.
Eligibility criteria
Inclusion Criteria: 1. Male and female aged 50 to 90 years old; 2. In accordance with the diagnostic criteria for "mild cognitive impairment due to Alzheimer's disease" and "Dementia" from the National Institutes of Health National Institute on Aging-Alzheimer's Association (NIA-AA) (2011); 3. The Hamilton depression rating scale/17 edition (HAMD) total score\<10; 4. The clinical dementia rating (CDR) is 0.5 or above; 5. Neurological examination: no obvious signs; 6. Participants should have a caregiver stable and reliable. 7. Education: primary school (grade 6) or above. They have the ability to complete tests for cognitive ability and have the ability and time to complete regulation of cognitive training Exclusion Criteria: 1. Other causes of cognitive decline: cerebrovascular disease, central nervous system infection, CJD, Huntington's and Parkinson's disease, DLB, traumatic brain dementia, other physical and chemical factors (such as drugs, alcohol, CO), systemic disease (hepatic encephalopathy, pulmonary encephalopathy, etc.), intracranial occupation (a subdural hematoma, brain tumor), the endocrine system disease (thyroid disease, parathyroid disease), and vitamins deficiency or any other causes of dementia. 2. The history of nervous system diseases, including stroke, optic myelitis, Parkinson's disease, epilepsy, etc.); 3. Psychiatric patients, including schizophrenia or other mental illnesses, bipolar disorder, major depression, or delirium; 4. There are unstable or serious heart, lung, liver, kidney, and hematopoietic system diseases; Poor prognosis because of malignant diseases such as tumors. 5. Vision or hearing problems that lead to poor performance on cognitive tests; 6. Two years history of severe alcoholism, and drug abuse; 7. The researchers believe that the subjects could not complete the study. 8. Contraindication of MRI or PET scanning.
Study design
Enrollment target: 400 participants
Age groups: adult, older_adult
Timeline
Starts: 2021-11-22
Estimated completion: 2025-10-01
Last updated: 2024-11-25
Interventions
Other: No intervention
Primary outcomes
  • MMSE (once a year)
  • Clock drawing test (once a year)
  • Complex figure test (once a year)
Sponsor
Ruijin Hospital · other
All locations (1)
Ruijin Hospital affiliated to Shanghai Jiaotong University School of MedicineRecruiting
Shanghai, Shanghai Municipality, China